E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
cuts, abrasions and burns |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Confirmation of the non-inferiority of Leukichtan Gel versus Betaisodona Salbe in the treatment of superficial skin injuries (cuts, abrasions and burns) measured as amount of patients with complete epithelisation of the wound during the treatment period.
|
|
E.2.2 | Secondary objectives of the trial |
a) Confirmation of the non-inferiority of Leukichtan Gel versus Betaisodona Salbe in the treatment of skin injuries (cuts, abrasions and burns) measured as - amount of patients with complete granulation of the wound - enlargement of the granulated area of the wound - time until the complete epithelisation of the wound - wound infection, erythema, fibrin coating - pain evaluation by investigator and by patient (from the age of 5 years) via patient's questionnaire at every visit - evaluation of therapy success by investigator and by patient (from 5 years) via patient's questionnaire at every visit - over all evaluation of therapy success by investigator at the end of study b) the comparability of tolerance At study start and at every visit, the tolerance of therapy will be evaluated by investigator and by patient (from 5 years) via patient's questionnaire. Furthermore, investigator evaluates the over all tolerance at the end of study. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
· age: 7 months - 80 years · male or female Caucasians · voluntary participation in the study · existence of a written consent of the patient, for patients under 18 years of age additionally with signature of a legal representative · diagnosis: superficial, fresh cuts, abrasions or burns, grade I-II, not older than 2 days · Safe contraception (female patients) according to Pearl Index < 1 - fulfilled as follows: (one of the following items has to be answered with “yes”) - hormonal contraception via estrogens and progestogens for example: o Combined hormonal contraceptive pill (estrogens and progestogens) o Mini pill (progestogens only) o Contraceptive vaginal ring (ring with estrogens and progestogens) o Contraceptive Patch (estrogens and progestogens) o Intrauterine systems (IUS) (with progestogens) - sterilisation - Sexual abstinence (reliable statement) / vasectomised partner
|
|
E.4 | Principal exclusion criteria |
· injuries older than 2 days (corresponding to 48 hours) · cuts > 10 cm, abrasions or burns > 100 cm2 · severe concomitant diseases (i.e. liver-/kidney disorders, metabolism disorders, tumors in the anamnesis) · hyperthyreosis or other manifest thyroid disease · dermatitis herpetiformis Duhring · patient was or will be treated before or after the study with a radio-iodine-therapy · patient with bland adenomatous goiter · predisposed patient with autonomic adenomas resp. functional autonomy · known hypersensitivity / allergy against iodine or Sodium bituminosulfonate, pale or one of the other ingredients of the investigational product · simultaneous application of enzymatic wound treatment · simultaneous application of hydrogen peroxide and Taurolidin as well as disinfectants containing silver or wound dressings containing silver (formation of silver iodide) · simultaneous or shortly subsequent treatment with disinfectants containing quicksilver (risk of chemical burn due to formation of quicksilver iodide) · existence of diseases that require systemic application of antibiotics or steroids and/or topical administration of antibiotics or steroids in the area of the skin injury · oral and/or topical therapy with corticosteroids · application of other medicinal and/or cosmetical products that can influence the therapy during the study · alcohol, drugs or medicins abuse · physical or psycological diseases where the adherence to the protocol appears to be questionable · lacking compliance · pregnancy, lactation · first-time intake of hormonal contraceptives or change of contraceptives within the last 3 months · participation in another clinical trial within the last 30 days, planned participation in another clinical trial within the duration of this study · previous participation within this study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
visite 4 = final examination after 14 days treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
end of the trial = the last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |